Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 12:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: EX Clear all
Active, not recruiting Phase 1 Interventional

T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation

NCT03180216
View directory record Official record
Conditions
Viral Infections, Bone Marrow Transplant Infection
Interventions
Virus Specific T cells (VSTs)
Biological
Lead sponsor
Children's National Research Institute
Other
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 4, 2026, 12:23 AM EDT
Available No phase listed Expanded access

Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders

NCT03626285
View directory record Official record
Conditions
Benign Neoplasm, Bone Marrow Transplantation Recipient, Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm
Interventions
Bone Marrow Transplantation, CliniMACS CD34 Reagent System, Peripheral Blood Stem Cell Transplantation
Procedure · Device
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 70 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 4, 2026, 12:23 AM EDT
No Longer Available No phase listed Expanded access

Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)

NCT00826046
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Prochymal®
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
U.S. locations
3
States / cities
Beech Grove, Indiana • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2020 · Synced Sep 4, 2026, 12:23 AM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Azacytidine During Anti-tuberculosis Therapy

NCT03941496
View directory record Official record
Conditions
Tuberculosis, Pulmonary
Interventions
Azacitidine Injection
Drug
Lead sponsor
Andrew Dinardo
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 4, 2026, 12:23 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Impact of Removal of Exercise on Glycemic Control and Vascular Health in Older Active Adults

NCT05468255
View directory record Official record
Conditions
Glucose Intolerance, Exercise, Vascular Function
Interventions
removal of exercise
Other
Lead sponsor
Old Dominion University
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Sep 4, 2026, 12:23 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT

NCT06149403
View directory record Official record
Conditions
MPS-IH (Hurler Syndrome)
Interventions
Experimental: OTL-203, Active Comparator: Allo-HSCT
Genetic
Lead sponsor
Orchard Therapeutics
Industry
Eligibility
28 Days to 30 Months
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 4, 2026, 12:23 AM EDT
Completed Not applicable Interventional Results available

D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD

NCT01172873
View directory record Official record
Conditions
Obsessive Compulsive Disorder
Interventions
D-cycloserine, Exposure and Response Prevention (EX/RP)
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
12 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Sep 4, 2026, 12:23 AM EDT
Completed Phase 1 Interventional

Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease

NCT03158896
View directory record Official record
Conditions
Acute Graft Versus Host Disease
Interventions
MSCTC-0010 Dose Escalation
Biological
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 4, 2026, 12:23 AM EDT
Completed Not applicable Interventional

Exercise and Body Composition in Juvenile Idiopathic Arthritis

NCT02479373
View directory record Official record
Conditions
Arthritis, Juvenile
Interventions
Ren-Ex Machine, Dual-Emission X-ray Absorptiometry (DEXA) scan, Biodex dynamometer, Sub-maximal test, Quality of life questionnaires
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
10 Years to 21 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 4, 2026, 12:23 AM EDT
Terminated Phase 2 Interventional Results available

Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies

NCT03717480
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
ClinicMACs
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Sep 4, 2026, 12:23 AM EDT
Terminated Phase 1Phase 2 Interventional

Feasibility of the LUM Imaging System for Detection of Prostate Cancer

NCT03441464
View directory record Official record
Conditions
Prostate Cancer, Neoplasm, Residual
Interventions
LUM Imaging System
Combination Product
Lead sponsor
Lumicell, Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Sep 4, 2026, 12:23 AM EDT
Completed Phase 1 Interventional

Genetically Modified Lymphocytes to Treat HIV-Infected Identical Twins - Study Modifications

NCT00001409
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infection
Interventions
Interleukin-2
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 4, 2026, 12:23 AM EDT
Terminated Phase 1 Interventional

Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies

NCT01630564
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Aldesleukin, Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion, Umbilical Cord Blood-Derived Lymphocyte Therapy
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
6 Months and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2018 · Synced Sep 4, 2026, 12:23 AM EDT
Terminated Phase 1 Interventional

Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

NCT01312376
View directory record Official record
Conditions
Ovarian Carcinoma, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
OC-DC vaccine, Bevacizumab, cyclophosphamide 300 mg/m2/d for 3 days, fludarabine 30 mg/m2/d for 3 days, ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells
Biological · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 4, 2026, 12:23 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Low Dose Computed Tomography for Lung Cancer Screening

NCT03084835
View directory record Official record
Conditions
Smoking
Interventions
Usual Care, WEB+TXT, WEB+TXT+TTS
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Sep 4, 2026, 12:23 AM EDT
Completed No phase listed Observational

Spot Ex PMCF 01 Study

NCT07206615
View directory record Official record
Conditions
Presence of Spot Ex Endoscopic Marker
Interventions
Endoscopic marker
Other
Lead sponsor
Laborie Medical Technologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 4, 2026, 12:23 AM EDT
Completed Phase 1Phase 2 Interventional

Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer

NCT00006225
View directory record Official record
Conditions
Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases
Interventions
filgrastim, recombinant flt3 ligand, recombinant human thrombopoietin, recombinant interleukin-3, in vitro-treated peripheral blood stem cell transplantation
Biological · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Sep 4, 2026, 12:23 AM EDT
Active, not recruiting Not applicable Interventional Results available

DCD IIT: Evaluating the Safety of Utilizing Donor Hearts From Donation After Circulatory Death (DCD) Donors

NCT05462041
View directory record Official record
Conditions
Organ Transplant
Interventions
DBD Donor Heart Transplantation, DCD Donor Heart Transplantation
Other · Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 4, 2026, 12:23 AM EDT
Withdrawn Phase 1 Interventional

Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2

NCT03209869
View directory record Official record
Conditions
Neuroblastoma, Relapsed Neuroblastoma, Recurrent Neuroblastoma, Osteosarcoma
Interventions
Ex vivo Expanded and Activated Haploidentical Donor NK Cells, Hu14.18-IL2
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
7 Months to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 12, 2022 · Synced Sep 4, 2026, 12:23 AM EDT
Terminated Phase 3 Interventional

DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension

NCT00389675
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan, Guanfacine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
85
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 4, 2026, 12:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures

NCT04085887
View directory record Official record
Conditions
Brain Tumor
Interventions
Panitumumab-IRDye800, Pinpoint-IR9000 endoscopic/handheld device, Explorer Air camera, PDE-NEO-II
Drug · Device
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 25 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 4, 2026, 12:23 AM EDT
Not listed Phase 1Phase 2 Interventional

Safety Evaluation of ART352-L in Subjects Undergoing Posterolateral Spinal Fusion

NCT04378543
View directory record Official record
Conditions
Degenerative Spondylolisthesis
Interventions
ART352-L
Biological
Lead sponsor
Ankasa Regenerative Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Rochester, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Sep 4, 2026, 12:23 AM EDT
Active, not recruiting Phase 1 Interventional

Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A

NCT03818763
View directory record Official record
Conditions
Hemophilia A
Interventions
Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2033
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 4, 2026, 12:23 AM EDT
Completed Phase 1Phase 2 Interventional

A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

NCT03653247
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Plerixafor, Busulfan, BIVV003
Biological · Drug · Genetic
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 40 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
5
States / cities
Oakland, California • Sacramento, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 4, 2026, 12:23 AM EDT